Xenon Pharmaceuticals Inc. (Nasdaq: XENE) announced that it has commenced dosing patients in a Phase 2 clinical trial of XEN801 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE